Drospirenone in combination with estrogens: For contraception and hormone replacement therapy

Climacteric

Volumn 8, Issue SUPPL. 3, 2005, Pages 19-27

  Oelkers, W H K ^a  

^a Endokrinologikum Berlin   (Germany)

Author keywords

Angeliq ; Drospirenone; Hormone replacement therapy; Oral contraceptive; Progesterone; Progestogens; Renin angiotensin aldosterone system; Yasmin

Indexed keywords

ALDOSTERONE ANTAGONIST; CYPROTERONE ACETATE; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

BLOOD PRESSURE; BODY WEIGHT; CARCINOMA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTRACEPTION; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM; HORMONE SUBSTITUTION; HUMAN; HYPERPLASIA; MENOPAUSAL SYNDROME; MENSTRUATION; POSTMENOPAUSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; WATER RETENTION;

ALDOSTERONE ANTAGONISTS; ANDROSTENES; CONTRACEPTIVES, ORAL; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; HYPERTENSION; PROGESTERONE CONGENERS; RENIN-ANGIOTENSIN SYSTEM;

EID: 27744554128     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130500330341     Document Type: Review

References (18)

1. Nichols M, Robinson G, Bounds W, et al. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception 1993;47:367-76
2. Rosenberg M. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-82
3. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996;61:166-71
4. Oelkers W, Schöneshöfer M, Schultze G, et al. Prolonged infusions of Ile-5-angiotensin II in sodium replete and deplete man: effects on aldosterone, ACTH, cortisol, blood pressure and electrolyte balance. J Clin Endocrinol Metab 1978;46:402-13
5. Crane M, Harris J. Effect of estrogens and gestagens on the renin-aldosterone system in oral contraceptives and high blood pressure. In Fregly M, Fregly M, eds. Oral Contraceptives and High Blood Pressure. Gainesville, USA: Dolphin Press, 1974:100-19
6. Crane M, Harris J. Effect of estrogens and gestagens on exchangeable sodium. In Fregly M, Fregly M, eds. Oral Contraceptives and High Blood Pressure. Gainesville, USA: Dolphin Press, 1974:159-68
7. Oelkers W, Blümel A, Schöneshöfer M, et al. Effects of ethinylestradiol on the renin-angiotensin-aldosterone-system and on plasma transcortin in women and men. J Clin Endocrinol Metab 1976;43:1036-40
8. Saruta T, Saade G, Nagahama S, et al. Effects of angiotensin II analog on blood pressure, renin and aldosterone in women on oral contraceptives and in toxemia. Gynecol Obstet Invest 1981;12:11-20
9. Oelkers W. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Eur J Contracept Reprod Health Care 2002;7(Suppl 3):19-26; discussion 42-3
10. Oelkers W, Schöneshöfer M, Blümel A. Effects of progesterone and four synthetic progestagens on sodium balance and the renin-aldosterone system in man. J Clin Endocrinol Metab 1974;39:882-90
11. Pollow K, Jucham N, Elger W, et al. Dihydrospirorenone (ZK30595): a novel synthetic progestogen. Characterization of binding to different proteins. Contraception 1992;46:561-74
12. Muhn P, Fuhrmann U, Fritzemeier K, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. In Steroid receptors and antihormones. Ann NY Acad Sci 1995;761:311-31
13. Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991;73:837-42
14. Rosenbaum P, Schmidt W, Helmerhorst F, et al. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur J Contracept Reprod Health Care 2000;5:16-24
15. Godsland I, Crook D, Wynn V. Low-dose oral contraceptives and carbohydrate metabolism. Am J Obstet Gynecol 1990;163:348-53
16. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21
17. Schürmann R, Holler T, Beenda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004;7:189-96
18. Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 2003;6 (Suppl 3):49-54